CER 227185: Interim Phase I/II data
In a dose-escalation Phase I/II trial, 3 of 10 evaluable patients taking CER
Gathering data...
Products & Solutions
About Biocentury
Contact
Privacy & Legal
- Follow Us
Gathering data...
In a dose-escalation Phase I/II trial, 3 of 10 evaluable patients taking CER